Dcr3 Levels in Blood and Urine on Renal and Patient Prognosis in Patients With Acute Kidney Injury

NCT05735093 | Unknown DMC

• 1 other identifier: 2022/009
• Study Type: observational
• Target: 98
• Locations: 1 country
• Sites: 1

Brief Summary

Kidney diseases represent a global public health problem due to the aging of the population, the increasing prevalence of diabetes, hypertension, obesity and immune disorders. TNF-superfamily ligands are heterotrimeric transmembrane proteins with a molecular structure characterized by the presence of a TNF homology domain that binds to cysteine-rich regions of specific TNF-superfamily receptors. The tumor necrosis factor (TNF) superfamily consists of ligands and receptors that modulate adaptive immunity regulation, hematopoiesis, morphogenesis, as well as different disease states, including cancer and diabetes. DcR3 is found increased in a variety of cancer cells and various inflammatory tissues and is considered a potential biomarker to predict inflammatory disease progression and cancer metastasis. While increasing DcR3 expression may be possible to treat inflammatory diseases and enhance tissue repair, decreasing DcR3 expression may increase tumor apoptosis and suppress tumor growth in vivo. The study will be carried out with the prospective examination of patients without anuria and who developed Acute Kidney Injury or on the basis of Acute Kidney Disease on Chronic Kidney Disease. Sixty patients and 30 age- and gender matched control healthy individuals that accept enrollment in the study will be followed up by the Nephrology Department in Kırıkkale University Faculty of Medicine for 2 years. The aim of this study was to investigate the relationship between blood and urine DcR 3 levels on the effects of renal and patient prognosis in patients with Acute Kidney Injury as a predictor or an auxiliary test in prediction.

Conditions

Acute Kidney Injury

Keywords

DcR levels, renal prognosis, patient survival, acute kidney injury

Outcome Measures

Primary Outcomes (1)

• Renal Survival

  Dobling of serum creatinine and kidney replacement therapy initiation

  12 months

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

18-90 years old Male and female Patients with acute kidney injury

You may qualify if:

• Patients 18 years and older
• Agree to participate in the study
• Patients with previously normal kidney function and Chronic Kidney Disease patients not receiving replacement therapy
• The patient is not anuric
• Malignant and inflammatory, autoimmune disease not having a history.

You may not qualify if:

• Non-Acute kidney injury dialysis procedures (Intox etc.)
• Chronic kidney disease patients receiving dialysis treatment
• Renal replacement therapy was started due to acute kidney injury in an external center, patients referred to our center
• Pediatric age patients
• Malignancy
• Chronic inflammatory and autoimmune disease

Sponsors & Collaborators

• Kırıkkale University: lead

Study Sites (1)

Kirikkale University

Kırıkkale, Yahsihan, 71450, Turkey (Türkiye)

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Blood and urine

MeSH Terms

Conditions

Acute Kidney Injury

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases

Study Officials

• UCLER KISA, Prof

  Kırıkkale University

  STUDY CHAIR

Central Study Contacts

BETUL DENIZ GOZMEN

CONTACT

+905050910351; peynir@gmail.com

ARİF ALPER KIRKPANTUR, Prof

CONTACT

+905065028795; alperkirkpantur@yahoo.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dr Betul Deniz Gozmen

Study Record Dates

• First Submitted: February 9, 2023
• First Posted: February 21, 2023
• Study Start: February 1, 2023
• Primary Completion: January 31, 2024
• Study Completion: February 1, 2024
• Last Updated: February 21, 2023

Record last verified: 2023-02

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)